Literature DB >> 9738047

Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs.

J S Bergmann1, G L Woods.   

Abstract

The reliability of the ESP Culture System II (herein referred to as ESP II) for testing susceptibilities of Mycobacterium tuberculosis isolates to isoniazid, rifampin, ethambutol, and streptomycin was evaluated by comparing results to those of the method of proportion (MOP), which was considered the reference method, for 20 clinical isolates and 30 challenge strains provided by the Centers for Disease Control and Prevention (CDC). Clinical isolates also were tested with the BACTEC TB 460 system; these results agreed with those obtained by the MOP for all isolates and all drugs, except the high concentration of isoniazid, for which agreement was 95%. After resolution of discrepancies, levels of agreement between ESP II and MOP for the clinical isolates were 95 and 100%, respectively, for the low and high concentrations of isoniazid, 100% for rifampin and ethambutol, and 95% for streptomycin. For the 30 challenge isolates, ESP II results for both concentrations of isoniazid agreed with the expected results in all cases, whereas agreement was 93% for both rifampin and streptomycin and 90% for ethambutol. All discrepancies with the CDC isolates were due to failure of ESP II to correctly classify resistant strains. By testing isolates yielding discrepant ethambutol and streptomycin results with a lower concentration of both drugs in the ESP II system, agreement increased to 93% for ethambutol and 100% for streptomycin. For the clinical isolates, the times to an ESP II result of susceptible (means +/- standard errors of the means) were 8.47 +/- 0.12 days (range, 7 to 10 days) and 8.73 +/- 0.29 days (range, 5 to 11 days) when the inoculum was prepared from a McFarland equivalent and from a seed bottle, respectively. The time to an ESP II result of resistant varied by drug and method of inoculum preparation, ranging from 5.50 +/- 0.22 days for ethambutol with the inoculum prepared from a McFarland standard to 8. 0 days for ethambutol with the inoculum prepared from a seed bottle. These data suggest that the ESP II system is a rapid and reliable method for testing susceptibilities of M. tuberculosis isolates to isoniazid and rifampin. Performance, however, may be suboptimal for ethambutol and streptomycin. Testing additional ethambutol-resistant and streptomycin-resistant strains with two concentrations of both drugs is necessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738047      PMCID: PMC105091     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  3 in total

1.  Mycobacterial cross contamination during radiometric culturing.

Authors:  A M Vannier; J J Tarrand; P R Murray
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

2.  Clinical evaluation of difco ESP culture system II for growth and detection of mycobacteria.

Authors:  G L Woods; G Fish; M Plaunt; T Murphy
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

3.  The resurgence of tuberculosis: is your laboratory ready?

Authors:  F C Tenover; J T Crawford; R E Huebner; L J Geiter; C R Horsburgh; R C Good
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

  3 in total
  13 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Reliability of the MB/BacT system for testing susceptibility of Mycobacterium tuberculosis complex isolates to antituberculous drugs.

Authors:  F Brunello; R Fontana
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Comparison of susceptibility testing of Mycobacterium tuberculosis using the ESP culture system II with that using the BACTEC method.

Authors:  P Ruiz; F J Zerolo; M J Casal
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis.

Authors:  Walter G Park; William R Bishai; Richard E Chaisson; Susan E Dorman
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

5.  Evaluation of the VersaTREK system compared to the Bactec MGIT 960 system for first-line drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  M Espasa; M Salvadó; E Vicente; G Tudó; F Alcaide; P Coll; N Martin-Casabona; M Torra; D Fontanals; J González-Martín
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

6.  Evaluation of a novel kit for use with the BacT/ALERT 3D system for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  Jim Werngren; Lisbeth Klintz; Sven E Hoffner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 7.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 8.  General and advanced diagnostic tools to detect Mycobacterium tuberculosis and their drug susceptibility: a review.

Authors:  Md A Gazi; Md R Islam; Mohammad G Kibria; Z Mahmud
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-06       Impact factor: 3.267

9.  Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.

Authors:  I J Eltringham; S M Wilson; F A Drobniewski
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

10.  Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pascale Bemer; Thomas Bodmer; Juerg Munzinger; Monique Perrin; Véronique Vincent; Henri Drugeon
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.